anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Symptomatic lumbar spinal stenosis (sLSS) is a common syndrome affecting the human spine characterized by age related degeneration of the lumbar discs and facet joints resulting in pain, limited function and compromised quality of life. In a healthy spine, global and local spinal loads during static posture and dynamic motion will have minimal effects on the spinal canal. However, spinal loads altered by the presence of sLSS may result in further narrowing of the spinal canal and compression of the neural elements or in overloading of the already degenerated lumbar segments possibly eliciting typical pain symptoms. This study assesses spinal imbalance and motion in patients with sLSS and elicits fatigue via back exercises and compares spinal imbalance and motion before and after the fatigue exercise and compares these to healthy controls, allowing to associate sLSS-specific motion patterns to paraspinal muscle fatigue. Additional data generated using magnetic resonance tomography allows detecting and assessing differences in muscle degeneration between sLSS patients and healthy controls. Radiological images from the spine in upright position using EOS, a specialized low-dose x-ray unit will be obtained to allow the calculation of the actual clinical global and local spinal imbalance. Furthermore, this study investigates the outcome of the decompression surgery during a second study visit scheduled 1 year postoperatively. The data obtained here are pilot data that will be critical for designing a larger clinical trial and produce important information for adapting musculoskeletal spine models to simulate spinal imbalance and motion and further defining meaningful outcome parameters.
Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
Myocardial ischemia-reperfusion injury (MIRI) significantly contributes to the high incidence of complications and mortality associated with acute myocardial infarction. Recently, injectable electroconductive hydrogels (IECHs) have emerged as promising tools for replicating the mechanical, electroconductive, and physiological characteristics of cardiac tissue. Herein, we aimed to develop a novel IECH by incorporating irbesartan as a drug delivery system (DDS) for cardiac repair. Our approach involved merging a conductive poly-thiophene derivative (PEDOT: PSS) with an injectable dual-network adhesive hydrogel (DNAH) comprising a catechol-branched polyacrylamide network and a chitosan-hyaluronic acid covalent network. The resulting P-DNAH hydrogel, benefitting from a high conducting polymer content, a chemically crosslinked network, a robust dissipative matrix, and dynamic oxidation of catechol to quinone exhibited superior mechanical strength, desirable conductivity, and robust wet-adhesiveness. In vitro experiments with the P-DNAH hydrogel carrying irbesartan (P-DNAH-I) demonstrated excellent biocompatibility by cck-8 kit on H9C2 cells and a rapid initial release of irbesartan. Upon injection into the infarcted hearts of MIRI mouse models, the P-DNAH-I hydrogel effectively inhibited the inflammatory response and reduced the infarct size. In conclusion, our results suggest that the P-DNAH hydrogel, possessing suitable mechanical properties and electroconductivity, serves as an ideal IECH for DDS, delivering irbesartan to promote heart repair.
The intervention for the experimental group implements a digital and interactive reminiscence program, starting with a preparation phase to select participants based on predefined criteria. Personalized content is developed for each individual, creating digital profiles that include photographs, music, videos, and significant life anecdotes tailored to evoke emotional memories. Care staff receive training on using the software and reminiscence techniques to facilitate the intervention. The implementation phase includes group and individual digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each. These sessions present selected digital content to promote discussion and memory sharing. Interactive activities, such as games and exercises, foster active participation, while the facilitator encourages participants to share stories and emotions, creating a supportive environment.
PURPOSE:The title cosmetic prepared by forming a film of gel from a combination of (A) the first component sol, obtained through addition of a specific lactate to an aqueous polyvinylalcohol, with (B) the second component sol, obtained through  addition of borax to an aqueous solution of sodium alginate, etc. CONSTITUTION:A bivalent metal lactate or chloride is added to an aqueous polyvinyl alcohol to form a sol as the first component (A). Borax is added to an aqueous solution of Na or K or ethanolamine salt of alginic acid to form a sol as the  second component (B). The first component (A) is applied to the skin to form a  film, to which the second component (B) is applied. The components (A) and (B)  are gelatinized to give a pack cosmetic at a high film formation rate because of the  reaction of both. The film can be readily stripped from the skin by fingertips. The  gel film of (A) has a great hydration ability, and retains the gel state for a long  time without drying.
Persons living with HIV infection (PLWH) have a 2-fold higher risk of myocardial infarction and are twice as likely to develop cardiovascular disease accounting for a significant global burden of disease. While the mechanism underlying this excess risk remains poorly understood, studies demonstrate that atherosclerosis in the setting of HIV is distinct and characterized by heightened arterial inflammation as assessed by FDG-PET/CT. HIV and antiretroviral medication can worsen cardiometabolic parameters. Thus a therapeutic strategy that can lower lipids, inflammation, and improve glycemic parameters may be even more advantageous in HIV. Bempedoic acid (BA, an inhibitor of ATP citrate lyase), is safely tolerated, significantly lowers LDL-C and inflammatory markers (on top of statin therapy), and is FDA approved for individuals with heterozygous familial hypercholesterolemia or with established ASCVD who require additional LDL-C lowering. Additionally, BA has a protective effect on glycemic parameters and may reduce adiposity. Given the key role of lipids and inflammation in atherosclerosis in HIV, the purpose of this proof-of-concept mechanistic trial is to evaluate the impact of BA on the biology of HIV-associated atherosclerosis. This is a randomized placebo controlled study of effectively treated PLWH aged 40 years and older with either known CVD or 1 CVD risk factor to study the effect of BA on arterial inflammation (assessed by FDG-PET/CT), lipid levels, biomarkers of inflammatory/immune activation, cardiometabolic indices, and non-calcified plaque in the coronary arteries (assessed by CCTA). This multicenter trial will include PLWH enrolled at UCSF and UCLA. Long term collaborators at MGH will serve as the core facility for the imaging end-points. There are three specific aims for the: Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial): Aim 1: To determine whether BA can safely reduce arterial inflammation including carotid plaque as assessed by FDG-PET/CT; Aim 2: To determine whether BA improves cardiometabolic measures (lipid, inflammatory, glycemic and adipose parameters) among PLWH. Exploratory objectives will be to assess BA's effect (vs. placebo) on glycemic as well as adipose tissue measures (HbA1c, HOMA IR, and adipose tissue volumes); Aim 3: To evaluate the impact of BA on non-calcified coronary plaque volume as measured by coronary CT angiography (CCTA).
PURPOSE:To produce homogeneous seamless capsules having uniform size by providing an auxiliary tank having a level control structure between the liq. coolant tank and pump to easily keep the liq. level in a capsule forming vessel constant. CONSTITUTION:The liq. coolant c is sent to the capsule forming vessel 4 from the coolant tank 5 by pumps 50 and 54, and the coolant is circulated through a capsule recovery pipe 71 and a capsule recovery vessel 7 and recovered in the tank 5. A composite jet current contg. the current of a filler (b) having fluidity in the current of a film forming material (a)insoluble in the coolant (c) is continuously formed in the current of the coolant (c) in the vessel 4. The composite jet current is successively cut to a specified length in the current of the coolant (c), and the cut pieces are successively formed into a specified shape in the current of the coolant (c). In this case, an auxiliary tank 9 having a level control structure is provided between the tank 5 and the pumps 50 and 54.
The dose should be individually titrated for each patient beginning with 20 mg three times daily. Doses in the range of 20 mg to 40 mg three times a day have been shown to be effective. At least 3 days should be allowed before increasing the nicardipine hydrochloride capsules dose to ensure achievement of steady-state plasma drug concentrations.

Concomitant Use with Other Antianginal Agents 

  1. Sublingual NTG may be taken as required to abort acute anginal attacks during nicardipine hydrochloride capsules therapy.
  2. Prophylactic Nitrate Therapy: Nicardipine hydrochloride capsules may be safely co-administered with short- and long-acting nitrates.
  3. Beta-blockers: Nicardipine hydrochloride capsules may be safely co-administered with beta-blockers (see Drug Interactions).
OBJECTIVES: Cannabis is used by one-third of people living with chronic pain to alleviate their symptoms despite warnings from several organizations regarding its efficacy and safety. We currently know little about self-medication practices (use of cannabis for therapeutic purposes without guidance), mainly since the legalization of recreational cannabis in countries such as Canada has expanded the scope of this phenomenon. This study aimed to describe legal cannabis self-medication for pain relief in people living with chronic pain and to explore perceptions of the effectiveness and safety of cannabis.
METHODS: A cross-sectional descriptive study was performed among 73 individuals living with chronic pain and using cannabis (Quebec, Canada). Data collection using telephone interviews occurred in early 2023.
RESULTS: Results indicated that 61.6% of participants reported using cannabis without the guidance of a health care professional (self-medication). Surprisingly, among those, 40.0% held a medical authorization. Overall, 20.6% of study participants were using both medical and legal nonmedical cannabis. Different pathways to self-medication were revealed. Proportion of women versus men participants self-medicating were 58.2% versus 70.6% ( P =0.284). In terms of perceptions, 90.4% of the sample perceived cannabis to be effective for pain management; 72.6% estimated that it posed no or minimal health risk.
DISCUSSION: Cannabis research is often organized around medical versus nonmedical cannabis but in the real-world, those 2 vessels are connected. Interested parties, including researchers, health care professionals, and funding agencies, need to consider this. Patients using cannabis feel confident in the safety of cannabis, and many of them self-medicate, which calls for action.
Fruquintinib was administered orally on 21 consecutive days in a 28-day treatment cycle. All patients were dose-optimized for the first cycle of fruquintinib - oral fruquintinib 3 mg/day in the first week; if tolerated, oral fruquintinib 4 mg/day in the second week; if still tolerated, then the dose was increased to 5 mg/day in the third week. From the second cycle, patients were given the maximum dose that they have tolerated in the first cycle.
Liver sinusoidal endothelial cells (LSECs) have an important role in hepatic ischemia‑reperfusion injury (I/R), but the specific molecular mechanism of action is unknown. LSEC proliferation is regulated and fenestration is maintained via the Sentrin/SUMO‑specific protease 1 (SENP1)/hypoxia‑inducible factor‑1α (HIF‑1α) signaling axis under hypoxic conditions. In the present study, a hypoxia‑reoxygenation (H‑R) injury model was established using mouse LSECs to explore the relationship between SENP1 and H‑R injury in vitro, and the specific underlying mechanism was identified, revealing new targets for the clinical attenuation of hepatic I/R injury. Following the culture of LSECs under H‑R conditions, it was demonstrated that the expression of SENP1 was upregulated by reverse transcription‑quantitative polymerase chain reaction and western blotting (WB). In addition, scanning electron microscopy indicated that fenestrae damage was increased, a Cell Counting Kit‑8 assay demonstrated that the proliferation of cells was impaired and flow cytometry showed that apoptosis was increased. After silencing SENP1 expression with short interfering RNA, the proliferation activity of LSECs decreased, the fenestrae damage increased, the apoptosis rate increased and the expression levels of SENP1, HIF‑1α, heme oxygenase and Bcl‑2 were downregulated (as demonstrated by WB), while the expression levels of apoptosis‑related proteins, cleaved‑caspase‑3 and Bax, were upregulated. Enzyme‑linked immunosorbent assay detection showed that the level of vascular endothelial growth factor in the supernatant decreased and the level of IL‑6 and TNF‑α increased. Following the administration of an HIF‑1α signaling pathway agonist, the situation was reversed. These results therefore suggested that SENP1 attenuated the reduction in proliferation, apoptosis and fenestration of LSECs observed following H‑R injury through the HIF‑1α signaling pathway. In conclusion, SENP1 may attenuate H‑R injury in LSECs in a HIF‑1α signaling pathway‑dependent manner.
Selinexor 40mg weekly for up to 12 cycles. Each cycle will be 28 days in length.
This project pilots the use of educational video games designed to help youth gain awareness of the risk of mental health issues associated with regular marijuana use. By playing the Back to Reality video games, youths may absorb knowledge about where and how to access community care for symptoms associated with psychosis and problematic cannabis use. The purpose of this study is to pilot test the use of the Back to Reality series at increasing awareness of the social and emotional implications of underage substance use.

This study explores the effects of the Back to Reality video games compared to control video games (no content about mental health and addiction). Street involved and homeless youth registered with Good Shepherd services between the ages of 16 and 19 years of age will be recruited. The results will be assessed using quantitative questionnaires and qualitative interviews. The data will be statistically analyzed for significant differences in knowledge about the risk of psychosis linked to marijuana use among vulnerable youth. The qualitative interview assesses the participants understanding and views of potential emotional, social, and psychiatric sequelae associated with excessive marijuana use during.
Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.
BACKGROUND: Urinary stone disease is a prevalent health issue worldwide, with varying incidence influenced by multiple factors. This study aims to provide the first comprehensive analysis of urinary stone composition in Azerbaijan.
METHODS: A retrospective study was conducted on 1465 patients, aged 1‒83 years, who underwent biochemical urinary stone analysis at the Department of Renal Diseases and Organ Transplantation, Azerbaijan State Security Service Military Hospital, between April 2015 and December 2023. Stone samples were analyzed using Fourier transform infrared (FTIR) spectroscopy. Statistical analyses were performed using the IBM® SPSS software version 29.0.
RESULTS: The cohort had a median age of 45 years, with a male-to-female ratio of 1.65:1. Calcium oxalate stones were the most common (56.2%), followed by uric acid (33.7%), struvite (5.3%), cystine (2.5%), calcium phosphate (1.9%), and xanthine (0.1%) stones. Men had a higher prevalence of calcium oxalate and uric acid stones, while women had more struvite stones. Mixed stones were common, particularly among uric acid and struvite stones. Significant differences in stone composition were observed between age groups and genders, with uric acid stones found predominantly in older individuals.
CONCLUSION: This study highlights the predominance of calcium oxalate stones and the elevated prevalence of uric acid stones in Azerbaijan, emphasizing the need for tailored diagnostic and therapeutic approaches. The high prevalence of mixed stones underscores the complexity of urinary stone disease and the need for comprehensive metabolic evaluation and individualized preventive strategies.
Ischaemic diseases such as critical limb ischaemia and myocardial infarction affect millions of people worldwide1. Transplanting endothelial cells (ECs) is a promising therapy in vascular medicine, but engrafting ECs typically necessitates co-transplanting perivascular supporting cells such as mesenchymal stromal cells (MSCs), which makes clinical implementation complicated2,3. The mechanisms that enable MSCs to facilitate EC engraftment remain elusive. Here we show that, under cellular stress, MSCs transfer mitochondria to ECs through tunnelling nanotubes, and that blocking this transfer impairs EC engraftment. We devised a strategy to artificially transplant mitochondria, transiently enhancing EC bioenergetics and enabling them to form functional vessels in ischaemic tissues without the support of MSCs. Notably, exogenous mitochondria did not integrate into the endogenous EC mitochondrial pool, but triggered mitophagy after internalization. Transplanted mitochondria co-localized with autophagosomes, and ablation of the PINK1-Parkin pathway negated the enhanced engraftment ability of ECs. Our findings reveal a mechanism that underlies the effects of mitochondrial transfer between mesenchymal and endothelial cells, and offer potential for a new approach for vascular cell therapy.
NEW MATERIAL:An amidinopiperidine derivative shown by the formulaI(A is O or S; R is phenyl, pyridyl, naphthyl, indanyl, or tetrahydronaphthyl which may have 1-3 substituent groups selected from halogen, alkyl, alkenyl, aralkyl, alkoxy, alkanoylamino, nitro, cyano, etc.; n is 0-2) and its acid addition salt. EXAMPLE:1-Amidino-4-piperidinepropionic acid phenyl ester hydrochloride. USE:Having an anticomplementary action, allergic inflammation suppressing action, protease inhibiting action, etc., useful as a drug. PROCESS:A compound shown by the formula II or its salt or its reactive derivative is reacted with a compound shown by the formula III (R<1> is halogen, etc.) or its sulfite derivative, and, if necessary, hydrogenated, to give a compound shown by the formulaI.
Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
Abstract The present invention relates to compositions having bedbug repellent activity and methods for controlling and/or repelling bedbugs. The compositions of the invention are useful, for example, for eradication of established bedbug colony infestations and/or for prophylactic application to prevent establishment of bedbug colonies. It is within the scope of the present invention to control, detect and/or repel bedbugs by combining the compositions with other treatments exemplified by infrared irradiation, production of sonic airwaves, and the like. The present invention provides for compositions comprising one or more compounds having bedbug repellant activity. In certain exemplary embodiments, the compounds may be, for example, naturally occurring semiochemicals or analogs of naturally occuring semiochemicals, wherein such analogs include structural analogs as well as functional analogs (i.e. compounds with only minimal structural similarity, but which exhibit one or more desirable activities of a naturally occurring semiochemical, including, but not limited to, bedbug repellent activity).
PURPOSE: Balantidium coli, is a protozoa that can infect humans. Balantidium coli infection is mostly asymptomatic, but can cause of diarrhea, abdominal pain and sometimes perforated colon. There are only few previous reports regarding the infant balantidiasis and there is a little information about its clinical signs and treatment. In Islamic countries pig farming and consumption is prohibited and reservoir host is unknown.
METHODS: 1.5 years old boy showed sever anorexia and diarrhea. The affected infant was depressed. The evaluation of fecal examination revealed a large number of B. coli trophozoites and cysts leaded us to an uncommon presentation of B. coli in the infant.
RESULTS: A few reports of human balantidiasis from Iran seems quite extraordinary. Wild boars have been proposed the responsible for transmission of human infection in Iran.
CONCLUSION: However, this report as the first report of infant balantidiasis in Iran supports the role of other sources and domestic or wild animals as reservoir hosts for B. coli in Iran.
PURPOSE:To obtain an antiulcer agent containing a mucopolysaccharide which is produced by extracellular secretion from a specific bacterial strain belonging to the genus Chlorella as an active ingredient, having strong antiulcer action on various ulcers, being non-toxic, capable of readily purifying and collecting in a large amount. CONSTITUTION:This antiulcer agent contains a muco polysaccharide extracellularly produced and secreted from Chlorella sp. K-4035 strain belonging to the genus Chlorella as active ingredient. This mucepolysaccharide has the following properties: Physical property: white powder; color reaction: positive to Molisch reaction, phenol sulfuric acid reaction, etc., and negative to ninhydrin reaction and iodine starch reaction, etc.; elementary analysis: C 38.14+ or -1.59%, H 6.28+ or -0.29%, N 1.38+ or -0.34; molecular weight: 800000-1200000; pH: 4.5-5.5; solubility: soluble in water, insoluble in alcohol, acetone, etc.; constitutional sugar: rhamnose, arabinose, mannose and uronic acid. Furthermore, the muco polysaccharide is obtained e.g. from the culture filtrate after culturing Chlorella sp. K-4035 strain in a liquid medium at 30 deg.C for 4 days.